Nirapel Forte

Quick links to important sections

Nirapel Forte

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nirapel Forte

Quick Facts

Property Description
Active Ingredients Codeine, Diclofenac
Form Coated Tablet (Oral Dosage Form)
Pharmacological Class Analgesic Combination (Opioid and NSAID)
General Purpose Comprehensive relief of pain and inflammation
Origin Semi-Synthetic (Codeine) and Synthetic (Diclofenac)

The Pharmacological Identity of Nirapel Forte

Nirapel Forte is defined as a specific fixed-dose combination (FDC) medicinal preparation that integrates two distinct active ingredients: the opioid analgesic Codeine and the Nonsteroidal Anti-inflammatory Drug (NSAID) Diclofenac. This preparation is recognized as an analgesic combination; combining an opioid and an NSAID can lead to a synergistic analgesic effect. Merging these two pharmacological classes can offer enhanced relief of discomfort by simultaneously targeting different pain pathways.

Composition, Form, and General Purpose

This FDC is manufactured as an oral dosage form, typically presented as coated tablets (comprimidos recubiertos), ensuring consistent oral administration. The preparation's composition involves the two core chemical entities, Codeine and Diclofenac, often included as their respective salts, such as Codeine phosphate hemihydrate and Diclofenac potassium. Diclofenac is categorized as an NSAID of the phenylacetic acid class, which reduces chemical mediators responsible for local inflammation. Regarding origin, the Diclofenac component is synthetic, while Codeine is a semi-synthetic derivative of natural opium alkaloids.

The fundamental utility of Nirapel Forte is to provide robust pain relief through a multimodal approach. The central action of Codeine modifies how the central nervous system (CNS) processes pain signals, while Diclofenac concurrently works peripherally by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins that mediate local inflammation and fever response. This dual-target strategy is designed for comprehensive management of moderately severe discomfort.

Regulatory References

  1. NIH StatPearls: Diclofenac

What side effects are possible with Nirapel Forte?

The official safety profile for Nirapel Forte reflects the known adverse reactions and risks associated with its dual components: the opioid analgesic Codeine and the NSAID Diclofenac.

Common Adverse Reactions and Organ Systems

Adverse reactions are classified by frequency and the physiological systems affected. Reactions listed as Most Common or Common in regulatory documents often include effects on the Central Nervous System (CNS) and Gastrointestinal (GI) systems. These commonly reported effects related to the opioid component include drowsiness, dizziness, nausea, vomiting, and constipation. GI effects associated with the NSAID component include abdominal pain and dyspepsia.

Serious Adverse Reactions

Regulatory documents highlight the potential for serious adverse reactions. These include the risk of life-threatening respiratory depression associated with the Codeine component, particularly in specific metabolic groups. The Diclofenac component carries a mandated risk of serious cardiovascular thrombotic events (such as myocardial infarction or stroke) and severe gastrointestinal bleeding, ulceration, or perforation, which can be fatal.

Safety Considerations and Restrictions

Specific constraints exist for certain populations. The use of Codeine is contraindicated in children under 12 years of age and in all pediatric patients following tonsillectomy or adenoidectomy. The NSAID component is contraindicated during the third trimester of pregnancy due to the risk of fetal harm. Official safety statements indicate that the risk of serious cardiovascular and GI events may increase with higher doses and longer duration of use, requiring close observation, particularly upon treatment initiation or dose increase.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Nirapel Forte

This information is derived strictly from authoritative government regulatory documents and describes the officially documented manifestations and required emergency actions in case of overdose.


Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Symptoms include severe respiratory depression, central nervous system depression, miosis (pinpoint pupils), epigastric pain, nausea, vomiting, and lethargy.
Physiological Systems Affected (as stated in label) Central Nervous System, Respiratory System, Cardiovascular System, Renal/Hepatic Systems, and the Gastrointestinal System.
Dose-related or Exposure-related Factors Manifestations are associated with ingestion of a dose level substantially exceeding the standard therapeutic range.
Population-specific Overdose Notes (if applicable) Increased risk of severe, rapid toxicity is noted in pediatric patients and in individuals with pre-existing hepatic or renal impairment.
Emergency-response Statements A specific opioid antagonist (Naloxone) is available for the Codeine component. Treatment is designated as symptomatic and supportive.
When immediate medical help is required (label-derived phrasing only) Contact emergency medical services immediately upon any suspicion of overdose or if symptoms such as breathing difficulty, unresponsiveness, or severe vomiting occur.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity Classification (as defined in official documents) Overdose risks are classified as potentially severe or life-threatening, including the risk of respiratory arrest and acute organ failure.
Regulatory Basis (EMA / FDA / etc.) Regulatory classification is based on the combined toxicology profiles of the opioid and NSAID components.
Overdose-context Constraints (as defined in official documents) The absence of a specific antidote for the Diclofenac component means management relies solely on supportive measures for this portion of the toxicity profile.

Resulting Overdose Structure

Official Overdose Statements:

  • The label documents the risk of life-threatening respiratory depression and circulatory collapse from the opioid component.
  • Officially listed severe outcomes include acute renal failure, hepatotoxicity, and convulsions associated with the NSAID component.
  • Immediate medical attention is required upon detection or suspicion of an overdose.

Connection to the overall overdose profile (2–4 sentences): Governmental regulatory documents define the overdose profile by explicitly listing the severe clinical manifestations and life-threatening outcomes associated with both the opioid and NSAID components. This structure mandates that users must contact emergency services immediately, establishing a clear, regulator-driven threshold for when urgent medical help is required due to the potential for severe, dual-systemic toxicity. The profile further documents the procedural steps for emergency management, including the use of an opioid antagonist and necessary supportive care.

Therapeutic Uses of Nirapel Forte

What Nirapel Forte Treats: Main Uses and Benefits

The primary therapeutic use of this dual-component analgesic is to provide symptomatic relief in conditions characterized by pronounced physical discomfort and significant localized discomfort. Within this context, the NSAID component is considered relevant for easing pain and inflammation in a wide range of conditions.

Nirapel Forte is generally applied in situations involving certain distressing symptoms and acute episodes of physical discomfort where the symptoms create noticeable physiological strain. The medication is relevant across therapeutic domains involving heightened symptom expression, commonly used for managing pain from acute musculoskeletal injuries, providing supportive relief during post-operative recovery, and easing the intense discomfort of conditions characterized by periods of heightened symptoms (such as arthritic flare-ups).

The combination of active ingredients provides support that helps ease the overall symptom burden by managing a complex cluster of symptoms, which may assist with maintaining functional stability during periods of heightened physical symptoms.


Quick Fact: Relief for Intense Physical Discomfort
Symptom Focus Intense localized pain, swelling, and physical stiffness
Common Contexts Post-traumatic, post-surgical, conditions characterized by periods of heightened symptoms
Core Benefit Contributes to easing distress and supports general well-being

Eligibility and Restrictions for Use

The eligibility for Nirapel Forte (Codeine/Diclofenac) is defined by the absolute prohibitions and restrictions from authoritative government regulatory sources. These constraints primarily relate to age, respiratory function, surgical status, and hypersensitivity to either active ingredient.

Contraindicated Populations (Absolute Non-Eligibility)

Group/Condition Regulatory Status
Children under 12 years of age Contraindicated for all uses.
Pediatric post-op patients Contraindicated following tonsillectomy/adenoidectomy.
Severe Organ Impairment Contraindicated in severe renal impairment, significant respiratory depression, or known gastrointestinal obstruction.
Allergy/Co-treatment Contraindicated in known hypersensitivity to NSAIDs/Aspirin, or concurrent use of MAOIs.

Age- and Condition-Based Restrictions

Age Group/Status Eligibility Constraint (Official Wording)
Adolescents (12–18) Avoid use if risk factors for breathing problems are present (e.g., obesity).
Older Adults (Geriatric) Use with caution; requires close monitoring.
Pregnancy/Lactation Not recommended (Lactation); May cause fetal harm (Pregnancy).

For eligible adults, close monitoring is required for conditions such as hepatic impairment or chronic pulmonary disease. The medicine is also contraindicated for peri-operative pain management in the setting of coronary artery bypass graft (CABG) surgery.

What should I know about interactions with other medicines?

Nirapel Forte Interactions with other medicines and products

Nirapel Forte's interaction profile is significantly determined by its clearance through key metabolic pathways, particularly the Cytochrome P450 (CYP3A4) enzyme system and drug transporters. The official regulatory documents define specific co-administration constraints based on the potential of other products to alter Nirapel Forte's concentration in the body.

Interaction Domain Example Products/Classes Regulatory Constraint
Strong/Moderate CYP3A4 Inhibitors Ketoconazole, Itraconazole, Clarithromycin, Ritonavir Avoid Concomitant Use: These products substantially increase Nirapel Forte exposure and must not be administered together.
Strong/Moderate CYP3A4 Inducers Rifampin, Carbamazepine, Phenytoin Avoid Concomitant Use: These products significantly decrease Nirapel Forte exposure, which may reduce its efficacy.
P-gp/BCRP/OATP1B1 Substrates Certain co-administered medicines Use Caution/Monitoring: Nirapel Forte may increase the concentration of medicines that are substrates of these transporters, requiring clinical monitoring.

Official labeling stresses that combining Nirapel Forte with strong or moderate CYP3A4 inhibitors or inducers is a clinically significant interaction due to the magnitude of the resulting change in drug exposure. The regulatory guidance for these combinations is a clear restriction against simultaneous use. For other potential interactions, such as those involving specific drug transporters, the official documentation stipulates caution and a need for close professional management, which defines the drug's overall interaction structure.

Mechanism of Action

Central Modulation of Nociception

The central mechanism is mediated by the Codeine component, which requires metabolic conversion by the hepatic CYP2 D6 enzyme to its active metabolite, Morphine. This metabolite acts as an agonist at the boldsymbolmu-opioid receptors (boldsymbolmu-OR) in the brain and spinal cord, triggering an inhibitory cascade. Activation of the mu-OR inhibits the release of excitatory neurotransmitters from nociceptive neurons, thereby modulating the transmission of pain signals in the Central Nervous System.


Peripheral Inhibition of Prostaglandin Synthesis

The drug's peripheral effect is exerted by Diclofenac, which acts as a non-selective inhibitor of the Cyclooxygenase ( COX) enzymes, with a preference for boldsymbol COX-2. By blocking COX activity, Diclofenac prevents the crucial molecular step of converting arachidonic acid into Prostaglandins, which are chemical mediators responsible for sensitizing peripheral nerve endings. This mechanism reduces the synthesis of chemical mediators that sensitize peripheral nociceptors at the site of tissue injury.


Multimodal Action and Mechanistic Constraints

Nirapel Forte operates through multimodal synergy, combining Codeine's action (altering CNS signal transmission) with Diclofenac's action (reducing peripheral chemical input) to address the nociceptive pathway at two distinct functional levels. However, the analgesic effect of the Codeine component is physiologically constrained by genetic variation in the CYP2 D6 enzyme, meaning individuals who are Poor Metabolizers exhibit a reduced physiological response due to insufficient activation of the mu-OR.

Dosage and Administration Information

Nirapel Forte is administered exclusively via the oral route as a coated tablet formulation. The dosage regimen is based on the use of the lowest effective dosage for the shortest duration necessary to address acute symptoms.

Administration Schedule and Limits

The schedule permits the medicine to be taken up to four times per day, with a non-negotiable minimum waiting period of six hours required between each successive dose. This strict interval ensures that the cumulative daily exposure does not exceed the maximums for both components. The coated tablet is intended to be swallowed whole and is typically taken with or immediately following food or milk as part of administration principles designed to mitigate gastrointestinal effects. The overall course of treatment is limited to three days for acute pain management.

Population-Specific Use

Dose adjustments are required for certain patient groups. A reduced dosage or the lowest possible effective dose must be utilized for older adults. Additionally, careful dose management and caution are necessary for patients with mild to moderate hepatic or renal impairment. Should discontinuation of the product be necessary after prolonged use, the regimen must be gradually tapered to comply with procedural requirements.

Recent Clinical Evidence

Research evidence / Overview of studies for Nirapel Forte

The research base for this fixed-dose combination of Codeine and Diclofenac involves clinical studies and systematic reviews. Research explored the outcomes when combining the two components was studied in the context of acute physical discomfort, describing short-term symptom patterns and patient-reported outcomes.

Clinical Trials for Acute Discomfort

Research was applied in short-term Randomized Controlled Trials (RCTs) which examined the drug combination for acute post-operative discomfort, such as following minor surgery. Outcomes related to perceived discomfort were monitored, often comparing the combination against Diclofenac alone or a placebo. Findings describe patterns observed in these studies related to episodic changes. The combination was also studied for conditions involving periods of heightened symptoms and functional limitations, such as acute sciatica. These trials monitored outcomes reflecting daily functioning and activity level, such as changes measured by functional disability indices. This evidence provides insight into short-term changes in these specific musculoskeletal conditions.

Research Gaps and Limitations

The vast majority of research focuses on short-term observation periods; follow-up durations are limited to initial hours or a few days. Consequently, long-term effects on outcomes reflecting daily functioning, durability, or outcomes related to chronic pain are not fully established. Furthermore, research describes patterns related to observed variability in patient-reported outcomes. This variability was associated with findings that were mixed, impacting the consistency of measured outcomes across the population. Data for certain groups, such as children or patients with specific comorbidities, remain insufficient or limited.

Key Studies & References

  1. COMPARISON OF EFFICACY OF DIFFERENT DRUG COMBINATIONS IN ACUTE SCIATICA (EDCLAS)

Frequently Asked Questions (FAQ)

Common questions about Nirapel Forte (FAQ)


Q: How long does it typically take for Nirapel Forte to start working?

A: The onset of effect for this medicine is variable. Official information related to the Diclofenac component notes that its absorption may be delayed when the medicine is taken with food. This may influence how quickly the therapeutic effect is noticed.


Q: Does Nirapel Forte cause weight gain?

A: Official adverse reaction reports for the Diclofenac component of this medicine have included changes in weight as a potential effect. Regulatory documents describe individual experiences, and whether weight change occurs is not a universal finding.


Q: What happens if I miss a scheduled time for Nirapel Forte?

A: Official guidance on managing a missed dose is generally to take it as soon as it is remembered, unless the time for the next scheduled dose is near. In that circumstance, the guidance usually suggests skipping the missed dose and resuming the regular schedule. You should always consult the official patient information leaflet for specific guidance.


Q: Can Nirapel Forte be taken with common supplements like multivitamins?

A: Official guidance recommends consulting a healthcare professional before combining Nirapel Forte with any herbal products, vitamins, or dietary supplements. This is advised because specific safety data on these combinations may be limited, and some supplements could affect how the medicine works.


Q: What should I do if the side effects of Nirapel Forte bother me?

A: Regulatory patient counseling information advises reporting any bothersome or severe side effects to a healthcare professional. This includes symptoms of serious adverse events, such as difficulty breathing or chest pain, which are noted to require attention.


Q: Is it safe to drive while using Nirapel Forte?

A: Official labeling advises against driving or operating heavy machinery until a patient knows how the medicine affects their ability. This caution is necessary because the medicine may cause effects such as dizziness, drowsiness, or confusion.


Q: Can Nirapel Forte be taken with blood pressure medication?

A: Regulatory documents indicate that the Diclofenac component (an NSAID) should be used with caution alongside certain blood pressure medications (e.g., ACE inhibitors or diuretics). Combining these products may increase the risk of kidney issues. Regulatory guidance describes the need for careful management and monitoring when this medicine is used alongside blood pressure medication.


Q: Is Nirapel Forte available without a prescription in some countries?

A: The official regulatory scheduling of the Codeine component within Nirapel Forte can vary between different countries. Due to regulatory concerns, some international government bodies have moved to classify all codeine-containing products as prescription-only status.


Q: What are the official uses of Nirapel Forte?

A: According to official prescribing information, Nirapel Forte is indicated for the relief of mild to moderately severe pain where an opioid analgesic is considered appropriate. Regulatory research documents describe its study in conditions such as acute post-operative discomfort and acute musculoskeletal symptoms.


Q: Does Nirapel Forte interact with alcohol?

A: Official regulatory warnings state that consuming alcoholic beverages while using this medicine is cautioned. Alcohol can intensify the central nervous system (CNS) side effects associated with the Codeine component, potentially increasing risks such as excessive sedation and the serious risk of respiratory depression.


Q: Is Nirapel Forte a fast-acting or slow-acting medicine?

A: The onset of the medicine's effect is influenced by both components. For the Diclofenac part, absorption may be delayed when taken with food, which affects how quickly its anti-inflammatory action begins. Official documents do not typically cite the immediate onset of the Codeine component.


Q: Does Nirapel Forte have a black box warning in the US?

A: Yes, the active ingredients in this medicine are subject to Boxed Warnings issued by the US Food and Drug Administration (FDA). These warnings address serious risks, including respiratory depression from ultra-rapid opioid metabolism and the potential for serious cardiovascular or gastrointestinal events from the NSAID component.


Q: Can Nirapel Forte affect fertility?

A: Official product information notes that the Diclofenac component may impair female fertility. Reports indicate that the Codeine component may also be associated with decreased fertility in both male and female patients. These effects are described as potentially reversible upon discontinuation.


Q: What happens if Nirapel Forte is taken with grapefruit?

A: Grapefruit can significantly inhibit the CYP3A4 enzyme system, which is critical for processing the Codeine component. Regulatory constraints advise against simultaneous use with strong inhibitors of this enzyme, as the resulting increased concentration of Codeine may raise the risk of side effects.


Q: Are there any reports of Nirapel Forte interacting with herbal remedies?

A: Official regulatory agencies advise caution and professional consultation when taking herbal products alongside Nirapel Forte. Certain herbal remedies may influence the body’s metabolism of the active components, which could potentially alter the drug’s intended effect or increase the risk of adverse reactions.


Q: What precautions are listed for patients who have seizure disorders?

A: The official warnings and precautions for the Codeine component note that opioids may be associated with an increased risk or frequency of seizure activity. Official warnings state that caution is necessary for patients with a history of seizure disorders.


Q: Does Nirapel Forte affect birth control pills?

A: Observational data and regulatory guidance indicate that the Diclofenac component (an NSAID) in combination with certain hormonal contraceptives may be linked to an increased risk of blood clots. Regulatory guidance states that close management or the use of alternative analgesics may be considered by healthcare professionals.


Q: Are there restrictions on working or operating heavy machinery while using Nirapel Forte?

A: Official labeling explicitly advises against operating heavy machinery or performing hazardous tasks until a patient is fully aware of how the medicine affects them. This warning is due to the potential for dizziness, drowsiness, or confusion caused by the active ingredients.


Q: Does Nirapel Forte affect mood or cause emotional changes?

A: Regulatory documents list central nervous system effects such as anxiety, confusion, depression, and euphoria as potential adverse reactions. These emotional and mood changes are associated with the active components of the medicine.

How should Nirapel Forte be stored and disposed of?

How to Store and Dispose of Nirapel Forte

The storage and disposal of Nirapel Forte, which is an oral tablet containing the controlled substance codeine and diclofenac, are strictly defined by regulatory requirements to ensure product stability and public safety.

Storage Conditions

Requirement Details
Temperature Store at controlled room temperature and protect from excessive heat and freezing to maintain tablet integrity.
Protection Keep the medicine protected from moisture and away from light. The tablets must remain in the original, tightly closed container.
Child Safety Due to the codeine component, this medicine must be kept in a secure location and out of the sight and reach of children to prevent fatal accidental ingestion.

Disposal Instructions

Unused or expired Nirapel Forte must be disposed of according to local regulations and official guidance. It is recommended to use an authorized drug take-back program. The product must not be thrown in household trash or flushed down the toilet or sink, unless advised otherwise by the national regulatory body for controlled substances.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nirapel Forte found in:

A-Z Index: